Edwards Lifesciences (EW) is a publicly traded Healthcare sector company. As of May 20, 2026, EW trades at $82.46 with a market cap of $47.44B and a P/E ratio of 43.66. EW moved +0.84% today. Year to date, EW is -1.43%; over the trailing twelve months it is +6.60%. Its 52-week range spans $64.01 to $87.89. Analyst consensus is strong buy with an average price target of $97.80. Rallies surfaces EW's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Edwards Lifesciences jumps on Q1 beat and higher 2026 sales, EPS outlook: Edwards Lifesciences (EW) shares are higher after the company reported Q1 sales of $1.65 billion and adjusted EPS of $0.78, exceeding expectations. Management raised full-year 2026 constant-currency sales growth guidance to 9%–11% and lifted the adjusted EPS midpoint to $2.95–$3.05.
| Metric | Value |
|---|---|
| Price | $82.46 |
| Market Cap | $47.44B |
| P/E Ratio | 43.66 |
| EPS | $1.89 |
| Dividend Yield | 0.00% |
| 52-Week High | $87.89 |
| 52-Week Low | $64.01 |
| Volume | 3.24M |
| Avg Volume | 0 |
| Revenue (TTM) | $6.30B |
| Net Income | $1.09B |
| Gross Margin | 77.87% |
17 analysts cover EW: 0 strong buy, 14 buy, 3 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $97.80.